Enhanc3D Genomics appoints Hazel Jones as chief operating officer
Enhanc3D Genomics has announced the appointment of Hazel Jones as chief operating officer.
This appointment marks part of the company’s goal to broaden the application of its technology and secure strategic collaboration agreements with pharmaceutical partners.
Hazel’s new role will involve leading, scaling and growing the company’s global business operations, playing an instrumental part in delivering its strategy to commercial and academic partners.
Hazel has over ten years of senior leadership experience in oncology research, and has significant expertise in developing partnerships aligned with complex operational procedures. Prior to Enhanc3D, she has worked in various roles at AstraZeneca, including executive product director of clinical data and head of business planning and operations in oncology R&D. Previously, she also worked as head of combination therapies at Cancer Research UK.
Dr Debora Lucarelli, chief executive officer of Enhanc3D Genomics, commented: “Hazel’s in-depth experience will be invaluable to the next stages of our development, as we seek to establish strategic partnerships to develop our extensive database of candidate therapeutic targets and disease biomarkers. With a proven ability to operate autonomously across large-scope projects, combined with a deep understanding of the pharmaceutical development process and a people-centric leadership approach, Hazel will play a central role in driving significant operational change to create maximum value for Enhanc3D Genomics’ stakeholders. I am delighted to welcome Hazel to the team.”
Commenting on her new role, Hazel Jones said: “I’m delighted to join the team at such an exciting stage of the Company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”